GSK Investigational Site

SAo JosE Do Rio PretoSP 15090-000

0 studies enrolling now · 1 studies all time

What they study most

Lung Cancer, Non-Small Cell

Studies at this site

• A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC) — Running, not enrolling